Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study

Wang, Guochang; Li, Linlin; Wang, Jiarou; Zang, Jie; Chen, Jingci; Xiao, Yu; Fan, Xiaoxuan; Zhu, Lin; Kung, Hank F.; Zhu, Zhaohui

doi:10.1007/s00259-022-06101-3

“…Besides, it is worth noting that the lower renal uptake of [ 68 Ga]Ga-P16-093 may contribute to the diagnosis of another urologic tumor, clear cell renal cell carcinoma (ccRCC), as the endothelial cells of the tumor-associated neovasculature of ccRCC express high levels of PSMA [ 29 ]. We have confirmed [ 68 Ga]Ga-P16-093 PET/CT demonstrates significantly better tumor detectability than 2-[ 18 F]FDG PET/CT for ccRCC patients [ 30 ]. By taking full advantage of the low urinary activity of [ 68 Ga]Ga-P16-093, it may be possible to expand the scope of application of this radiotracer and to identify genitourinary cancers more successfully than ever, which can result in better patient care and outcomes.…”

Section: Discussionsupporting

confidence: 65%

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

Wang

¹

,

Li

²

,

Zhu

³

et al. 2023

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Purpose We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [ 68 Ga]Ga-P16-093 and [ 68 Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. Methods Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent [ 68 Ga]Ga-P16-093 and [ 68 Ga]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. Results [ 68 Ga]Ga-P16-093 PET/CT detected more positive tumors than [ 68 Ga]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, [ 68 Ga]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 ± 10.2 vs. 11.4 ± 8.3, P < 0.001). For normal organs, [ 68 Ga]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 ± 6.1 vs . 29.3 ± 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 ± 7.1 vs . 20.9 ± 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 ± 2.6 vs. 7.6 ± 2.1, P < 0.001), liver (SUVmean: 7.0 ± 1.9 vs. 3.7 ± 1.3, P < 0.001), and spleen (SUVmean: 8.2 ± 3.0 vs. 5.2 ± 2.2, P < 0.001) than [ 68 Ga]Ga-PSMA-11 PET/CT. Conclusion [ 68 Ga]Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than [ 68 Ga]Ga-PSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that [ 68 Ga]Ga-P16-093 may serve as an alternative agent for detection of PCa. Trial registration 68 Ga-P16-093 and 68 Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered). URL of registry https://clinicaltrials.gov/ct2/show/NCT05324...

show abstract

“…Immunohistochemistry illustrates that PSMA, despite its nomenclature, can be also overexpressed on the endothelial cells of the neovasculature of nonprostate cancers such as renal carcinoma, well-differentiated thyroid carcinoma, hepatocellular carcinoma, lung adenocarcinoma, and glioma. [2][3][4][5][6][7] However, there is limited evidence for PSMA expression in neuroendocrine tumors, which are typically characterized by increased tumoral neovasculature and also PSMA expression. Only a few cases of NET with PSMA avidity in patients with a history of prostate cancer have been reported.…”

Section: Figurementioning

confidence: 99%

“…The tumor heterogeneity of NET in this case causes the discrepancy in FDG uptake between the primary tumor and the liver metastasis, 1 leading to incorrect tumor staging on 18 F-FDG PET/CT. Immunohistochemistry illustrates that PSMA, despite its nomenclature, can be also overexpressed on the endothelial cells of the neovasculature of nonprostate cancers such as renal carcinoma, well-differentiated thyroid carcinoma, hepatocellular carcinoma, lung adenocarcinoma, and glioma 2–7 . However, there is limited evidence for PSMA expression in neuroendocrine tumors, which are typically characterized by increased tumoral neovasculature and also PSMA expression.…”

mentioning

confidence: 99%

68Ga-PSMA PET/CT in Hepatic Metastasis From Pancreatic Neuroendocrine Tumor

Chen,

Lin,

Wang

et al. 2023

Clin Nucl Med

0

View full text Add to dashboard Cite

A 53-year-old man underwent both 18F-FDG and 68Ga-PSMA PET/CT to evaluate a mass in the left upper abdomen. The scans demonstrated intense uptake of both 18F-FDG and 68Ga-PSMA in the mass. However, a nodule in the left lobe of the liver showed increased uptake of 68Ga-PSMA, which was not FDG avid. Histopathological examination after surgical resection of the mass confirmed the diagnosis of pancreatic neuroendocrine tumor (G2). Subsequently, 68Ga-DOTATATE PET/CT demonstrated intense radioactivity of the nodule in the left lobe of the liver consistent with hepatic metastasis from neuroendocrine tumor.

show abstract

“…Recently, a new PSMA-targeting imaging agent, [ 68 Ga]Ga-P16-093, with a novel Glu-NH-CO-NH-Lys-Phe- O -carboxymethyl)-Tyr-HBED-CC group (Figure ) was successfully evaluated in humans. ,,,, By modifying the chelating group for Lu(III) chelation while maintaining the same PSMA binding moiety and linker (X = Glu-NH-CO-NH-Lys-Phe- O -carboxymethyl)-Tyr-) of this diagnostic imaging agent, [ 68 Ga]Ga-P16-093 was successfully transformed to the radionuclide therapy agents, [ 177 Lu]Lu-P17–087, [ 177 Lu]Lu-P17-088 (Approach #1) and [ 177 Lu]Lu-P19-065 (Approach #2) (see Figure ). To develop hetero-bivalent agents, an additional group, R = Gly-bisphosphonate, was strategically added for targeting both PSMA tumors and bone metastasis, resulting in the formation of two new hetero-bivalent targeting agents: [ 177 Lu]Lu- 1 and [ 177 Lu]Lu- 2 (Figures and ).…”

Section: Introductionmentioning

confidence: 99%

Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy

Zha,

Ploessl,

Choi

et al. 2023

Self Cite

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is an excellent target for imaging and radionuclide therapy of prostate cancer. Recently, [177Lu]Lu-PSMA-617 (Pluvicto) was approved by the FDA for radionuclide therapy. To develop hetero-bivalent agents targeting both PSMA and bone metastasis, [177Lu]Lu-P17-079 ([177Lu]Lu-1) and [177Lu]Lu-P17-081 ([177Lu]Lu-2) were prepared. In vivo biodistribution studies of [177Lu]Lu-PSMA-617, [177Lu]Lu-1, and [177Lu]Lu-2 in mice bearing PC3-PIP (PSMA positive) tumor showed high uptake in PSMA-positive tumor (14.5, 14.7, and 11.3% ID/g at 1 h, respectively) and distinctively different bone uptakes (0.52, 6.52, and 5.82% ID/g at 1 h, respectively). PET imaging using [68Ga]Ga-P17-079 ([68Ga]Ga-1) in the same mouse model displayed excellent images confirming the expected dual-targeting to PSMA-positive tumor and bone. Results suggest that [177Lu]Lu-P17-079 ([177Lu]Lu-1) is a promising candidate for further development as a hetero-bivalent radionuclide therapy agent targeting both PSMA expression and bone metastases for the treatment of prostate cancer.

show abstract

Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study

Cited by 17 publications

References 36 publications

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

68Ga-PSMA PET/CT in Hepatic Metastasis From Pancreatic Neuroendocrine Tumor

Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy

Contact Info

Product

Resources

About